Listeria monocytogenes-associated respiratory infections: a study of 38 consecutive cases
Journal Title: | Clinical microbiology and infection 2018, Vol.24 (12), p.1339.e1-1339.e5 |
Main Author: | Morgand, M |
Other Authors: | Leclercq, A , Maury, M.M , Bracq-Dieye, H , Thouvenot, P , Vales, G , Lecuit, M , Charlier, C |
Format: |
![]() |
Language: |
English |
Subjects: | |
Quelle: | Alma/SFX Local Collection |
Publisher: | England: Elsevier Ltd |
ID: | ISSN: 1198-743X |
Zum Text: |
SendSend as email
Add to Book BagAdd to Book Bag
Staff View

recordid: | cdi_hal_primary_oai_HAL_pasteur_02449011v1 |
title: | Listeria monocytogenes-associated respiratory infections: a study of 38 consecutive cases |
format: | Article |
creator: |
|
subjects: |
|
ispartof: | Clinical microbiology and infection, 2018, Vol.24 (12), p.1339.e1-1339.e5 |
description: | Listeria monocytogenes (Lm) is a foodborne human pathogen responsible for severe infections, including septicaemia, neurolisteriosis, and maternal–foetal and focal infections. Little is known about Lm-associated respiratory tract or lung infections. We conducted a retrospective study of culture-proven cases of Lm pleural infections and pneumonia reported to the French National Reference Centre for Listeria from January 1993 to August 2016. Thirty-eight consecutive patients with pleural infection (n = 32), pneumonia (n = 5), or both (n = 1) were studied; 71% of these were men. Median age was 72 (range 29–90). Two patients presented with concomitant neurolisteriosis. All patients but one reported at least one immunosuppressive condition (97%), with a median number of 2 (range 0–5), including 29% (8/28) with current exposure to immunosuppressive therapy and 50% (17/34) with ongoing neoplasia; 75% (21/28) reported previous pleural or pulmonary disease. Antibiotic therapy mostly consisted in amoxicillin (72%) associated with aminoglycoside in 32%. Chest-tube drainage was performed in 7/19 patients with empyema (37%); 25% of the patients (7/30) required intensive care management. In-hospital mortality reached 35% and occurred after a median time interval of 4 days (range 1–33 days). Three patients had recurrence of empyema (time interval of 1 week to 4 months after treatment completion). Altogether, only 13/31 patients (42%) diagnosed with Lm respiratory infection experienced an uneventful outcome at 2-year follow-up. Lm is a rare but severe cause of pneumonia and pleural infection in older immunocompromised patients, requiring prompt diagnosis and adequate management and follow-up. |
language: | eng |
source: | Alma/SFX Local Collection |
identifier: | ISSN: 1198-743X |
fulltext: | fulltext |
issn: |
|
url: | Link |
@attributes |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PrimoNMBib |
|